Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SurgiLight files vitiligo laser treatment in US:

This article was originally published in Clinica

Executive Summary

SurgiLight has submitted its EX-308 excimer laser to the US FDA for permission to market the product as a treatment for vitiligo, a skin disorder that leads to the loss of skin pigmentation. The laser is already approved for treating psoriasis. SurgiLight of Orlando, Florida, says that vitiligo is estimated to affect around 1-2% of the world population and around two to four million people in the US.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts